MORRIS PLAINS, N.J., Jan. 19, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the receipt of $5 million from Nycomed, GmbH, for reaching the first clinical milestone event under the license and collaboration agreement, entered into on July 11, 2008, for the worldwide rights to develop, manufacture and commercialize veltuzumab for the treatment of all non-cancer indications.
